Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.75 |
| ▸ | CA1 | P00915 | 5/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.52 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7572528 | 0.98 | CA2 (0.72) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL2919231 | 0.98 | CA2 (0.72) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL27698121 | 0.98 | CA2 (0.72) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL17573070 | 0.98 | CA2 (0.72) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL1360883 | 0.98 | CA2 (0.72) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL9625784 | 0.98 | CA2 (0.72) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL15111174 | 0.98 | CA2 (0.72) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL8059908 | 0.98 | CA2 (0.72) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL10885897 | 0.98 | CA2 (0.72) | CA2CA1MAPK1GRIK1GRIK2 | |
| SCHEMBL4659823 | 0.98 | CA2 (0.71) | CA2CA1MAPK1GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109328214-B | Molding compounds for 3D printing based on SAN copolymer and polyamide blends | 英力士苯领集团股份公司 | 2021-06-22 | — | — | CN | claimed |
| EP-2024349-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Abbott Laboratories (US) | 2009-02-18 | — | — | EP | claimed |
| WO-2007140439-A2 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-12-06 | — | — | WO | claimed |
| EP-1397137-A4 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL MYERS SQUIBB CO (US) | 2004-10-13 | — | — | EP | claimed |
| EP-1397137-A1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-03-17 | — | — | EP | claimed |
| WO-2002096426-A1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-05 | — | — | WO | claimed |
| CN-116267014-A | Cyclic deuterated gaboxadol and its use for treating psychotic disorders | CERTEGO治疗公司 | 2023-06-20 | — | — | CN | disclosed |
| CN-110650738-B | Compounds and methods for treating parasitic diseases | 博德研究所 | 2023-05-09 | — | — | CN | disclosed |
| CN-114901652-A | Substituted saturated and unsaturated N-heterocyclic carboxamides and related compounds for the treatment of medical disorders | 比亚尔R&D投资股份公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20220162211-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PARASITIC DISEASES | THE BROAD INSTITUTE, INC. (US) | 2022-05-26 | — | — | US | disclosed |
| CN-113661166-A | Process for the synthesis of diazabicyclo [6.2.0] decane-related compounds | 卫材R&D管理有限公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-109328214-B | Molding compounds for 3D printing based on SAN copolymer and polyamide blends | 英力士苯领集团股份公司 | 2021-06-22 | — | — | CN | disclosed |
| CN-112457486-A | Polyamides with light absorbers in the main chain and related methods | 施乐公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-112457484-A | Particles comprising polyamides with backbone internal light absorbers and related methods | 施乐公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-110650738-A | Compounds and methods for treating parasitic diseases | 博德研究所 | 2020-01-03 | — | — | CN | disclosed |
| CN-107937389-A | Assembled on array | 安捷伦科技有限公司 | 2018-04-20 | — | — | CN | disclosed |
| CN-101360498-A | Calcilytic compounds | SMITHKLINE BEECHAM CORP (US) | 2009-02-04 | — | — | CN | disclosed |
| EP-1397137-A4 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL MYERS SQUIBB CO (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1397137-A1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002096426-A1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162211-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PARASITIC DISEASES | PIGO, CAT, OAT | CA2 218/4885CA1 399/4885MAPK1 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.